OncoMatch/Clinical Trials/NCT06591819
Hypofractionated WPPT With HDR Boost
Is NCT06591819 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for prostate cancer.
This is a phase II study of ultrahypofractionated whole pelvis proton therapy with brachytherapy boost for patients with high risk or unfavorable intermediate risk prostate with elevated risk of lymph node involvement.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage T2C
High risk: T3a or Gleason Grade Group 4/5 or PSA >20 Unfavorable intermediate risk disease: at least one or more of the following: T2b-T2c, Gleason Grade Group 2/3, PSA 10-20, >50% of cores positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
No prior radiotherapy in the region of study
Cannot have received: radiation therapy
Prior radiation to the pelvis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06591819 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage T2C is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages